Literature DB >> 22017350

ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse model.

Hitomi Sudo1, Atsushi B Tsuji, Aya Sugyo, Yuriko Ogawa, Masashi Sagara, Tsuneo Saga.   

Abstract

Mesothelioma is an aggressive tumor caused by asbestos exposure, the incidence of which is predicted to increase globally. The prognosis of patients with mesothelioma undergoing conventional therapy is poor. Radiation therapy for mesothelioma is of limited use because of the intrinsic radioresistance of tumor cells compared with surrounding normal tissue. Thus, a novel molecular-targeted radiosensitizing agent that enhances the radiosensitivity of mesothelioma cells is required to improve the therapeutic efficacy of radiation therapy. ZDHHC8 knockdown reduces cell survival and induces an impaired G(2) /M checkpoint after X-irradiation in HEK293 cells. In the present study, we further analyzed the effect of the combination of ZDHHC8 knockdown and X-irradiation and assessed its therapeutic efficacy in mesothelioma models. SiRNA-induced ZDHHC8 knockdown in 211H and H2052 mesothelioma cells significantly reduced cell survival after X-irradiation. In 211H cells treated with ZDHHC8 siRNA and X-irradiation, the G(2) /M checkpoint was impaired and there was an increase in the number of cells with micronuclei, as well as apoptotic cells, in vitro. In 211H tumor-bearing mice, ZDHHC8 siRNA and X-irradiation significantly suppressed tumor growth, whereas ZDHHC8 siRNA alone did not. Immunohistochemical analysis showed decreased cell proliferation and induction of apoptosis in tumors treated with ZDHHC8 siRNA and X-irradiation, but not with ZDHHC8 siRNA alone. These results suggest that ZDHHC8 knockdown with X-irradiation induces chromosomal instability and apoptosis through the impaired G(2) /M checkpoint. In conclusion, the combination of ZDHHC8 siRNA and X-irradiation has the potential to improve the therapeutic efficacy of radiation therapy for malignant mesothelioma.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017350     DOI: 10.1111/j.1349-7006.2011.02126.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  14 in total

Review 1.  Protein palmitoylation and cancer.

Authors:  Pin-Joe Ko; Scott J Dixon
Journal:  EMBO Rep       Date:  2018-09-19       Impact factor: 8.807

2.  Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5.

Authors:  Hui Tian; Jui-Yun Lu; Chunli Shao; Kenneth E Huffman; Ryan M Carstens; Jill E Larsen; Luc Girard; Hui Liu; Jaime Rodriguez-Canales; Eugene P Frenkel; Ignacio I Wistuba; John D Minna; Sandra L Hofmann
Journal:  Mol Cancer Res       Date:  2015-01-08       Impact factor: 5.852

3.  Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.

Authors:  Aya Sugyo; Atsushi B Tsuji; Hitomi Sudo; Maki Okada; Mitsuru Koizumi; Hirokazu Satoh; Gene Kurosawa; Yoshikazu Kurosawa; Tsuneo Saga
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

4.  Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.

Authors:  Winn Aung; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Yoshinori Ukai; Katsushi Kouda; Yoshikazu Kurosawa; Takako Furukawa; Tsuneo Saga
Journal:  Oncotarget       Date:  2016-06-21

5.  Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor.

Authors:  Winn Aung; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Yoshinori Ukai; Katsushi Kouda; Yoshikazu Kurosawa; Takako Furukawa; Tsuneo Saga; Tatsuya Higashi
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

6.  Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model.

Authors:  Yasuhiro Ohshima; Hitomi Sudo; Shigeki Watanabe; Kotaro Nagatsu; Atsushi B Tsuji; Tetsuya Sakashita; Yoichi M Ito; Keiichiro Yoshinaga; Tatsuya Higashi; Noriko S Ishioka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-19       Impact factor: 9.236

7.  Drosophila ZDHHC8 palmitoylates scribble and Ras64B and controls growth and viability.

Authors:  Katrin Strassburger; Evangeline Kang; Aurelio A Teleman
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

8.  Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.

Authors:  Chisato Yoshida; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Tatsuya Kikuchi; Mitsuru Koizumi; Yasushi Arano; Tsuneo Saga
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

9.  Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.

Authors:  Aya Sugyo; Atsushi B Tsuji; Hitomi Sudo; Kotaro Nagatsu; Mitsuru Koizumi; Yoshinori Ukai; Gene Kurosawa; Ming-Rong Zhang; Yoshikazu Kurosawa; Tsuneo Saga
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with 90Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer.

Authors:  Aya Sugyo; Atsushi B Tsuji; Hitomi Sudo; Mitsuru Koizumi; Yoshinori Ukai; Gene Kurosawa; Yoshikazu Kurosawa; Tsuneo Saga; Tatsuya Higashi
Journal:  Int J Mol Sci       Date:  2018-09-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.